Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been given an average recommendation of “Hold” by the ten research firms that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $10.78.

Several brokerages recently commented on ZNTL. Morgan Stanley reiterated an “equal weight” rating and set a $8.00 price target (down from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a report on Monday, August 12th. Stifel Nicolaus reduced their target price on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, June 18th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, August 12th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $6.00 price target (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $4.22 on Friday. The firm has a market capitalization of $299.73 million, a price-to-earnings ratio of -1.27 and a beta of 1.70. The business has a 50 day simple moving average of $3.56 and a 200-day simple moving average of $8.36. Zentalis Pharmaceuticals has a 1 year low of $2.83 and a 1 year high of $22.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same period in the prior year, the firm earned ($1.85) EPS. As a group, analysts expect that Zentalis Pharmaceuticals will post -2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently modified their holdings of ZNTL. Quest Partners LLC bought a new position in Zentalis Pharmaceuticals in the fourth quarter worth approximately $38,000. Anfield Capital Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth $40,000. SG Americas Securities LLC bought a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $58,000. Algert Global LLC purchased a new position in Zentalis Pharmaceuticals in the second quarter valued at about $78,000. Finally, American Century Companies Inc. bought a new position in Zentalis Pharmaceuticals in the second quarter worth about $95,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.